Herantis Pharma Oyj

Helsinki Stock Exchange HRTIS.HE

Herantis Pharma Oyj Free Cash Flow for the year ending December 31, 2023: USD -5.12 M

Herantis Pharma Oyj Free Cash Flow is USD -5.12 M for the year ending December 31, 2023, a 46.53% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Herantis Pharma Oyj Free Cash Flow for the year ending December 31, 2022 was USD -9.57 M, a 15.37% change year over year.
Herantis Pharma Oyj Free Cash Flow for the year ending December 31, 2021 was USD -11.31 M, a -8.13% change year over year.
Herantis Pharma Oyj Free Cash Flow for the year ending December 31, 2020 was USD -10.46 M.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

Helsinki Stock Exchange: HRTIS.HE

Herantis Pharma Oyj

CEO	Dr. Antti Vuolanto D.Sc. (Tech)
IPO Date	June 11, 2014
Location	Finland
Headquarters	Bertel Jungin Aukio 1
Employees	11
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying CDNF-based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic version of the active parent as the preclinical xCDNF candidate for the treatment of PD and other neurodegenerative diseases; and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein that is in Phase I study in patients with PD. The company was incorporated in 2008 and is based in Espoo, Finland.

Key trends

Past 5 years